Drugs facing NCE-1 in 2021
1. List of Aliqopa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7511041 | BAYER HEALTHCARE | Fused azole-pyrimidine derivatives |
May, 2024
(1 year, 3 months from now) | |
| USRE46856 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
Oct, 2029
(6 years from now) | |
| US10383876 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
Mar, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9636344 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts |
Mar, 2032
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 14, 2022 |
| Orphan Drug Exclusivity (ODE) | Sep 14, 2024 |
Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient
NCE-1 date: September, 2021
Market Authorisation Date: 14 September, 2017
Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies
Dosage: POWDER;INTRAVENOUS
2. List of Alunbrig drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9012462 | TAKEDA PHARMS USA | Phosphorous derivatives as kinase inhibitors |
Apr, 2031
(8 years from now) | |
| US10385078 | TAKEDA PHARMS USA | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine |
Nov, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9273077 | TAKEDA PHARMS USA | Phosphorus derivatives as kinase inhibitors |
May, 2029
(6 years from now) | |
| US9611283 | TAKEDA PHARMS USA | Methods for inhibiting cell proliferation in ALK-driven cancers |
Apr, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 28, 2022 |
| Orphan Drug Exclusivity (ODE) | May 22, 2027 |
| New Indication (I) | May 22, 2023 |
Drugs and Companies using BRIGATINIB ingredient
NCE-1 date: April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)
Dosage: TABLET;ORAL
3. List of Bevyxxa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7598276 | PORTOLA PHARMS INC | Pharmaceutical salts and polymorphs of a factor Xa inhibitor |
Nov, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9555023 | PORTOLA PHARMS INC | Pharmaceutical salts and polymorphs of a factor Xa inhibitor |
Nov, 2026
(3 years from now) | |
| US8557852 | PORTOLA PHARMS INC | Methods of using crystalline forms of a salt of a factor Xa inhibitor |
Sep, 2028
(5 years from now) | |
| US8987463 | PORTOLA PHARMS INC | Methods of synthesizing factor Xa inhibitors |
Dec, 2030
(7 years from now) | |
| US8404724 | PORTOLA PHARMS INC | Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor |
Mar, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 23, 2022 |
Drugs and Companies using BETRIXABAN ingredient
NCE-1 date: June, 2021
Market Authorisation Date: 23 June, 2017
Treatment: Prophylaxis of pulmonary embolism; Prophylaxis of deep vein thrombosis (dvt); Prophylaxis of venous thrombosis; Inhibiting coagulation
Dosage: CAPSULE;ORAL
4. List of Calquence drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7459554 | ASTRAZENECA | Imidazopyrazine tyrosine kinase inhibitors |
Nov, 2026
(3 years from now) | |
| US9290504 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(9 years from now) | |
| US11059829 | ASTRAZENECA | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate |
Jul, 2036
(13 years from now) | |
| CN1898240B | ASTRAZENECA | Imidazole And Pyrazine Type Tyrosine Kinase Inhibitor |
Dec, 2014
(8 years ago) | |
| CN1898240A | ASTRAZENECA | Imidazopyrazine Tyrosine Kinase Inhibitors |
Dec, 2014
(8 years ago) | |
| CN106243113A | ASTRAZENECA | Imidazole As Selective Btk Inhibitors And Paradiazine |
Jul, 2032
(9 years from now) | |
| CN103889987A | ASTRAZENECA | As An Inhibitor Of Btk-4-Imidazole And -1--- Benzamide And 4 - - Imidazo Triazine -1--- Benzamide |
Jul, 2032
(9 years from now) | |
| CN103889987B | ASTRAZENECA | Imidazole As Selective Btk Inhibitors And Paradiazine |
Jul, 2032
(9 years from now) | |
| CN106243113B | ASTRAZENECA | As A Selective Btk Inhibitor And Pyrazine |
Jul, 2032
(9 years from now) | |
| IN200601290P4 | ASTRAZENECA | Imidazopyrazine Tyrosine Kinase Inhibitors |
Oct, 2024
(1 year, 8 months from now) | |
| IN249666B | ASTRAZENECA | Imidazopyrazine Tyrosine Kinase Inhibitors |
Oct, 2024
(1 year, 8 months from now) | |
| EP1675860A2 | ASTRAZENECA | Imidazo[1,5-A]Pyrazines As Tyrosine Kinase Inhibitors |
Oct, 2024
(1 year, 8 months from now) | |
| EP1675860B1 | ASTRAZENECA | Imidazo[1,5-A]Pyrazines As Tyrosine Kinase Inhibitors |
Oct, 2024
(1 year, 8 months from now) | |
| EP3689878B1 | ASTRAZENECA | 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors |
Jul, 2032
(9 years from now) | |
| EP3689878A1 | ASTRAZENECA | 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors |
Jul, 2032
(9 years from now) | |
| EP2734522B1 | ASTRAZENECA | 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors |
Jul, 2032
(9 years from now) | |
| EP2734522A1 | ASTRAZENECA | 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors |
Jul, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10239883 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors |
Jul, 2032
(9 years from now) | |
| US9758524 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(9 years from now) | |
| US10272083 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 31, 2022 |
Drugs and Companies using ACALABRUTINIB MALEATE ingredient
NCE-1 date: October, 2021
Market Authorisation Date: 03 August, 2022
Treatment: Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with chronic lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with small lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia; Treatment of adult patients with previously untreated small lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with small lymphocytic leukemia
Dosage: TABLET;ORAL
5. List of Calquence drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7459554 | ASTRAZENECA | Imidazopyrazine tyrosine kinase inhibitors |
Nov, 2026
(3 years from now) | |
| US9290504 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(9 years from now) | |
| US9796721 | ASTRAZENECA | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
Jul, 2036
(13 years from now) | |
| CN1898240B | ASTRAZENECA | Imidazole And Pyrazine Type Tyrosine Kinase Inhibitor |
Dec, 2014
(8 years ago) | |
| CN1898240A | ASTRAZENECA | Imidazopyrazine Tyrosine Kinase Inhibitors |
Dec, 2014
(8 years ago) | |
| CN106243113A | ASTRAZENECA | Imidazole As Selective Btk Inhibitors And Paradiazine |
Jul, 2032
(9 years from now) | |
| CN103889987A | ASTRAZENECA | As An Inhibitor Of Btk-4-Imidazole And -1--- Benzamide And 4 - - Imidazo Triazine -1--- Benzamide |
Jul, 2032
(9 years from now) | |
| CN103889987B | ASTRAZENECA | Imidazole As Selective Btk Inhibitors And Paradiazine |
Jul, 2032
(9 years from now) | |
| CN106243113B | ASTRAZENECA | As A Selective Btk Inhibitor And Pyrazine |
Jul, 2032
(9 years from now) | |
| IN200601290P4 | ASTRAZENECA | Imidazopyrazine Tyrosine Kinase Inhibitors |
Oct, 2024
(1 year, 8 months from now) | |
| IN249666B | ASTRAZENECA | Imidazopyrazine Tyrosine Kinase Inhibitors |
Oct, 2024
(1 year, 8 months from now) | |
| EP1675860A2 | ASTRAZENECA | Imidazo[1,5-A]Pyrazines As Tyrosine Kinase Inhibitors |
Oct, 2024
(1 year, 8 months from now) | |
| EP1675860B1 | ASTRAZENECA | Imidazo[1,5-A]Pyrazines As Tyrosine Kinase Inhibitors |
Oct, 2024
(1 year, 8 months from now) | |
| EP3689878B1 | ASTRAZENECA | 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors |
Jul, 2032
(9 years from now) | |
| EP3689878A1 | ASTRAZENECA | 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors |
Jul, 2032
(9 years from now) | |
| EP2734522B1 | ASTRAZENECA | 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors |
Jul, 2032
(9 years from now) | |
| EP2734522A1 | ASTRAZENECA | 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors |
Jul, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10239883 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors |
Jul, 2032
(9 years from now) | |
| US9758524 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(9 years from now) | |
| US10272083 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(11 years from now) | |
| US10167291 | ASTRAZENECA | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
Jul, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 21, 2026 |
| New Chemical Entity Exclusivity (NCE) | Oct 31, 2022 |
| New Indication (I) | Nov 21, 2022 |
Drugs and Companies using ACALABRUTINIB ingredient
NCE-1 date: October, 2021
Market Authorisation Date: 31 October, 2017
Treatment: Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with small lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with chronic lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with small lymphocytic leukemia; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia; Treatment of adult patients with previously untreated small lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab
Dosage: CAPSULE;ORAL
6. List of Giapreza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10548943 | LA JOLLA PHARMA | Method of treating low blood pressure |
Dec, 2029
(6 years from now) | |
| US10500247 | LA JOLLA PHARMA | Method of treating low blood pressure |
Dec, 2029
(6 years from now) | |
| US9867863 | LA JOLLA PHARMA | Method of treating low blood pressure |
Dec, 2029
(6 years from now) | |
| US10335451 | LA JOLLA PHARMA | Method of treating low blood pressure |
Dec, 2029
(6 years from now) | |
| US9572856 | LA JOLLA PHARMA | Method of treating low blood pressure |
Jul, 2031
(8 years from now) | |
| US9220745 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(11 years from now) | |
| US10493124 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(11 years from now) | |
| US11096983 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(11 years from now) | |
| US10028995 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(11 years from now) | |
| US11219662 | LA JOLLA PHARMA | Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II |
Jan, 2037
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 21, 2022 |
Drugs and Companies using ANGIOTENSIN II ACETATE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 21 December, 2017
Treatment: Increasing blood pressure with a rate of about 20 ng/kg/min to about 40 ng/kg/min angiotensin ii in a human subject having septic shock; Increasing blood pressure with an initial rate of about 20 ng/kg/min angiotensin ii in a human subject having septic shock, and titrating the rate up.; Treating low blood pressure with angiotensin ii with an initial rate of about 5 ng/kg/min to about 20 ng/kg/min in a subject having refractory hypotension or severe hypotension, and titrating the rate up; Treating low blood pressure with angiotensin ii with an initial rate of about 5 ng/kg/min to about 20 ng/kg/min in a subject having refractory hypotension or severe hypotension; Treating refractory hypotension with about 5 ng/kg/min to about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor; Treating hypotension with about 20 ng/kg/min to about 40 ng/kg/min angiotensin ii in a human subject having septic shock; Treating refractory hypotension with about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor; Maintaining mean arterial pressure of about 65 mmhg or higher with angiotensin ii in shock patients treated with catecholamines and reducing catecholamine use; Treating high output shock with angiotensin ii by increasing mean arterial pressure in patients treated with catecholamines and reducing catecholamine use; Treating low blood pressure with angiotensin ii at an initial rate of about 20 ng/kg/min and titrating down to achieve and/or maintain a map of about 65 mm hg or above; Treating distributive shock with angiotensin ii; Treating septic shock with angiotensin ii; Maintaining mean arterial pressure of about 65 mmhg or above with about 1 ng/kg/min to about 40 ng/kg/min angiotensin ii in hypotensive patients treated with vasopressin or a vasopressin analogue and reducing vasopressin or vasopressin analogue use; Treating hypotension with angiotensin ii in a patient receiving an angiotensin converting enzyme inhibitor
Dosage: SOLUTION;INTRAVENOUS
7. List of Goprelto drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11040032 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10857095 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10894012 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10987347 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10973811 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10933060 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10149843 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10420760 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10016407 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10231961 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10413505 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US9867815 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 14, 2022 |
Drugs and Companies using COCAINE HYDROCHLORIDE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 14 December, 2017
Treatment: Method for the induction of local anesthesia of the mucous membranes; Method of administering a local anesthetic to the mucous membranes in patients with hepatic impairment; Method of administering a local anesthetic to the mucous membranes in patients with renal impairment; Method of administering a local anesthetic to the mucous membranes; Method for the induction of local anesthesia prior to performing a procedure on, through, or adjacent to the mucous membranes; Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or renal impairment; Method of administering a local anesthetic to the mucous membranes in geriatric patients
Dosage: SOLUTION;NASAL
8. List of Idhifa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9512107 | CELGENE CORP | Therapeutically active compositions and their methods of use |
Jan, 2033
(9 years from now) | |
| US10093654 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Aug, 2034
(11 years from now) | |
| US9738625 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Aug, 2034
(11 years from now) | |
| US9732062 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Sep, 2034
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610125 | CELGENE CORP | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(7 years from now) | |
| US10294215 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Jan, 2033
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 1, 2024 |
| New Chemical Entity Exclusivity (NCE) | Aug 1, 2022 |
Drugs and Companies using ENASIDENIB MESYLATE ingredient
NCE-1 date: August, 2021
Market Authorisation Date: 01 August, 2017
Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation
Dosage: TABLET;ORAL
9. List of Ingrezza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8039627 | NEUROCRINE | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
Apr, 2031
(8 years from now) | |
| US10851104 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(13 years from now) | |
| US10851103 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(13 years from now) | |
| US10844058 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(13 years from now) | |
| US10065952 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(13 years from now) | |
| US10906902 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(13 years from now) | |
| US10919892 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(13 years from now) | |
| US10906903 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8357697 | NEUROCRINE | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
Nov, 2027
(4 years from now) | |
| US10952997 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(14 years from now) | |
| US10874648 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(14 years from now) | |
| US10857137 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(14 years from now) | |
| US10857148 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(14 years from now) | |
| US11040029 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(14 years from now) | |
| US10993941 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(14 years from now) | |
| US10912771 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(14 years from now) | |
| US11026939 | NEUROCRINE | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
Sep, 2038
(15 years from now) | |
| US11311532 | NEUROCRINE | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
Sep, 2038
(15 years from now) | |
| US11026931 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Aug, 2039
(16 years from now) | |
| US10940141 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Aug, 2040
(17 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 11, 2022 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
NCE-1 date: April, 2021
Market Authorisation Date: 11 April, 2017
Treatment: Treatment of tardive dyskinesia; Method of administering valbenazine while avoiding concomitant use of a strong cyp3a4 inducer; Method of treating tardive dyskinesia while avoiding concomitant use of a strong cyp3a4 inducer
Dosage: CAPSULE;ORAL
10. List of Kisqali drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8324225 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Jun, 2028
(5 years from now) | |
| US8685980 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
May, 2030
(7 years from now) | |
| US8415355 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Mar, 2031
(8 years from now) | |
| US9193732 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9416136 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Aug, 2029
(6 years from now) | |
| US8962630 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Dec, 2029
(6 years from now) | |
| US9868739 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(8 years from now) | |
| US10799506 | NOVARTIS | Ribociclib tablet |
Apr, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 13, 2022 |
| New Patient Population (NPP) | Dec 10, 2024 |
Drugs and Companies using RIBOCICLIB SUCCINATE ingredient
NCE-1 date: March, 2021
Market Authorisation Date: 13 March, 2017
Treatment: In combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; In combination with fulvestrant for the treatment of postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy; In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; In combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer; In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer
Dosage: TABLET;ORAL
11. List of Kisqali Femara Co-pack (copackaged) drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8324225 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Jun, 2028
(5 years from now) | |
| US8685980 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
May, 2030
(7 years from now) | |
| US8415355 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Mar, 2031
(8 years from now) | |
| US9193732 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9416136 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Aug, 2029
(6 years from now) | |
| US8962630 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Dec, 2029
(6 years from now) | |
| US9868739 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(8 years from now) | |
| US10799506 | NOVARTIS | Ribociclib tablet |
Apr, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 13, 2022 |
| New Patient Population (NPP) | Dec 10, 2024 |
Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient
NCE-1 date: March, 2021
Market Authorisation Date: 04 May, 2017
Treatment: Treatment of pre/perimenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; As initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer
Dosage: TABLET;ORAL
12. List of Macrilen drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6861409 | NOVO | Growth hormone secretagogues |
Aug, 2022
(6 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8192719 | NOVO | Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds |
Oct, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 20, 2024 |
| New Chemical Entity Exclusivity (NCE) | Dec 20, 2022 |
Drugs and Companies using MACIMORELIN ACETATE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 20 December, 2017
Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin
Dosage: FOR SOLUTION;ORAL
13. List of Nerlynx drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7399865 | PUMA BIOTECH | Protein tyrosine kinase enzyme inhibitors |
Dec, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7982043 | PUMA BIOTECH | Protein tyrosine kinase enzyme inhibitors |
Oct, 2025
(2 years from now) | |
| US9139558 | PUMA BIOTECH | Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
Oct, 2028
(5 years from now) | |
| US9630946 | PUMA BIOTECH | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
Oct, 2028
(5 years from now) | |
| US10035788 | PUMA BIOTECH | Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
Oct, 2028
(5 years from now) | |
| US9265784 | PUMA BIOTECH | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
Aug, 2029
(6 years from now) | |
| US9211291 | PUMA BIOTECH | Treatment regimen utilizing neratinib for breast cancer |
Mar, 2030
(7 years from now) | |
| US8790708 | PUMA BIOTECH | Coated tablet formulations and uses thereof |
Nov, 2030
(7 years from now) | |
| US8518446 | PUMA BIOTECH | Coated tablet formulations and uses thereof |
Nov, 2030
(7 years from now) | |
| US8669273 | PUMA BIOTECH | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
Jul, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 17, 2022 |
| New Indication (I) | Feb 25, 2023 |
| New Dosing Schedule (D) | Jun 28, 2024 |
Drugs and Companies using NERATINIB MALEATE ingredient
NCE-1 date: July, 2021
Market Authorisation Date: 17 July, 2017
Treatment: Extended adjuvant treatment of adult patients with early stage her2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab base therapy; Use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the metastatic setting; Extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer, to follow adjuvant trastuzumab based therapy
Dosage: TABLET;ORAL
14. List of Ozempic drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(3 years from now) | |
| US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6899699 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(1 year, 1 month ago) | |
| US8672898 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(1 year, 1 month ago) | |
| US9486588 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(1 year, 1 month ago) | |
| US8579869 | NOVO | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(4 months from now) | |
| US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 3 months from now) | |
| US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(2 years from now) | |
| US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(2 years from now) | |
| US11446443 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(2 years from now) | |
| US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(2 years from now) | |
| US11311679 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(2 years from now) | |
| US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(2 years from now) | |
| US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(2 years from now) | |
| US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(2 years from now) | |
| US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(2 years from now) | |
| US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(3 years from now) | |
| US11097063 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(3 years from now) | |
| US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(3 years from now) | |
| US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(3 years from now) | |
| USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(3 years from now) | |
| US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(4 years from now) | |
| US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(4 years from now) | |
| US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(9 years from now) | |
| US10335462 | NOVO | Use of long-acting GLP-1 peptides |
Jun, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Jan 16, 2023 |
| New Chemical Entity Exclusivity (NCE) | Dec 5, 2022 |
| New Dosing Schedule (D) | Mar 28, 2025 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 05 December, 2017
Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof; Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Dosage: SOLUTION;SUBCUTANEOUS
15. List of Parsabiv drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9278995 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Jul, 2030
(7 years from now) | |
| US9701712 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Jul, 2030
(7 years from now) | |
| US8377880 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Jul, 2030
(7 years from now) | |
| US8999932 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Feb, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11162500 | KAI PHARMS INC | Stable liquid formulation of AMG 416 (etelcalcetide) |
Jun, 2034
(11 years from now) | |
| US10344765 | KAI PHARMS INC | Stable liquid formulation of AMG 416 (etelcalcetide) |
Jun, 2034
(11 years from now) | |
| US9820938 | KAI PHARMS INC | Stable liquid formulation of AMG 416 (etelcalcetide) |
Jun, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 7, 2022 |
Drugs and Companies using ETELCALCETIDE ingredient
NCE-1 date: February, 2021
Market Authorisation Date: 07 February, 2017
Treatment: A method of treating secondary hyperparathyroidism (shpt)
Dosage: SOLUTION;INTRAVENOUS
16. List of Prevymis drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE46791 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(1 year, 3 months from now) | |
| US8513255 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(1 year, 3 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603384 | MERCK SHARP DOHME | Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative |
Feb, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 8, 2024 |
| New Chemical Entity Exclusivity (NCE) | Nov 8, 2022 |
Drugs and Companies using LETERMOVIR ingredient
NCE-1 date: November, 2021
Market Authorisation Date: 08 November, 2017
Treatment: NA
Dosage: TABLET;ORAL
17. List of Rhopressa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9096569 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US8450344 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US10174017 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(6 years from now) | |
| US10654844 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(6 years from now) | |
| US8394826 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Nov, 2030
(7 years from now) | |
| US9415043 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
| US10588901 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
| US9931336 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11021456 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US10532993 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US10882840 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US11028081 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(6 years from now) | |
| US11185538 | AERIE PHARMS INC | Compositions for treating glaucoma or reducing intraocular pressure |
Mar, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 18, 2022 |
Drugs and Companies using NETARSUDIL MESYLATE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 18 December, 2017
Treatment: Reduction of elevated intraocular pressure
Dosage: SOLUTION/DROPS;OPHTHALMIC
18. List of Rocklatan drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8450344 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US9096569 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US10654844 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(6 years from now) | |
| US10174017 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(6 years from now) | |
| US8394826 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Nov, 2030
(7 years from now) | |
| US9993470 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
| US10588901 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
| US9931336 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
| US9415043 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11021456 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US10532993 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US10882840 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US11028081 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(6 years from now) | |
| US11185538 | AERIE PHARMS INC | Compositions for treating glaucoma or reducing intraocular pressure |
Mar, 2034
(11 years from now) | |
| US11197853 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 18, 2022 |
| New Combination (NC) | Mar 12, 2022 |
Drugs and Companies using LATANOPROST; NETARSUDIL DIMESYLATE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 12 March, 2019
Treatment: Reduction of elevated intraocular pressure
Dosage: SOLUTION/DROPS;OPHTHALMIC
19. List of Rybelsus drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(3 years from now) | |
| US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10086047 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(8 years from now) | |
| US11382957 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(8 years from now) | |
| US9278123 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(8 years from now) | |
| US10960052 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid |
Dec, 2031
(8 years from now) | |
| US10933120 | NOVO | Compositions of GLP-1 peptides and preparation thereof |
Mar, 2033
(10 years from now) | |
| US10278923 | NOVO | Oral dosing of GLP-1 compounds |
May, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Jan 16, 2023 |
| New Product (NP) | Sep 20, 2022 |
| New Chemical Entity Exclusivity (NCE) | Dec 5, 2022 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 20 September, 2019
Treatment: Method of treating type 2 diabetes mellitus
Dosage: TABLET;ORAL
20. List of Rydapt drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222244 | NOVARTIS | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
Oct, 2022
(3 months ago) | |
| US7973031 | NOVARTIS | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
Oct, 2028
(5 years from now) | |
| US8575146 | NOVARTIS | Pharmaceutical uses of staurosporine derivatives |
Dec, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 28, 2022 |
| Orphan Drug Exclusivity (ODE) | Apr 28, 2024 |
Drugs and Companies using MIDOSTAURIN ingredient
NCE-1 date: April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy; Treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated hematological neoplasm (sm-ahn), or mast cell leukemia (mcl)
Dosage: CAPSULE;ORAL
21. List of Segluromet drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8080580 | MERCK SHARP DOHME | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Jul, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9439902 | MERCK SHARP DOHME | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(7 years from now) | |
| US9308204 | MERCK SHARP DOHME | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 19, 2022 |
| M | Sep 17, 2024 |
Drugs and Companies using ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET;ORAL
22. List of Steglatro drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8080580 | MERCK SHARP DOHME | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Jul, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 19, 2022 |
| M | Sep 17, 2024 |
Drugs and Companies using ERTUGLIFLOZIN ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET;ORAL
23. List of Steglujan drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(6 months ago) | |
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(3 years from now) | |
| US8080580 | MERCK SHARP DOHME | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Jul, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6699871
(Pediatric) | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(7 days ago) | |
|
US7326708
(Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(4 years from now) | |
| US9439901 | MERCK SHARP DOHME | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(7 years from now) | |
| US9308204 | MERCK SHARP DOHME | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 19, 2022 |
| M | Sep 17, 2024 |
Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET;ORAL
24. List of Symproic drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE46375 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Oct, 2026
(3 years from now) | |
| USRE46365 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Jan, 2028
(4 years from now) | |
| US9108975 | BDSI | Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same |
Nov, 2031
(8 years from now) | |
| US10952968 | BDSI | Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives |
May, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 23, 2022 |
Drugs and Companies using NALDEMEDINE TOSYLATE ingredient
NCE-1 date: March, 2021
Market Authorisation Date: 23 March, 2017
Treatment: Treatment of opioid-induced constipation
Dosage: TABLET;ORAL
25. List of Trulance drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7799897 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jun, 2022
(7 months ago) | |
| US7041786 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jan, 2028
(4 years from now) | |
| US10011637 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8637451 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Mar, 2022
(10 months ago) | |
| US9925231 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(8 years from now) | |
| US9610321 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(8 years from now) | |
| US9919024 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(8 years from now) | |
| US11319346 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Mar, 2032
(9 years from now) | |
| US9616097 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Aug, 2032
(9 years from now) | |
| US11142549 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 19, 2022 |
Drugs and Companies using PLECANATIDE ingredient
NCE-1 date: January, 2021
Market Authorisation Date: 19 January, 2017
Treatment: Elevation of intracellular cgmp resulting in increased intestinal fluid and accelerated transit; Chronic idiopathic constipation; Irritable bowel syndrome with constipation
Dosage: TABLET;ORAL
26. List of Tymlos drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8748382 | RADIUS HEALTH INC | Method of drug delivery for bone anabolic protein |
Oct, 2027
(4 years from now) | |
| US8148333 | RADIUS HEALTH INC | Stable composition comprising a PTHrP analogue |
Nov, 2027
(4 years from now) | |
| US7803770 | RADIUS HEALTH INC | Method of treating osteoporosis comprising administration of PTHrP analog |
Apr, 2031
(8 years from now) | |
| US10996208 | RADIUS HEALTH INC | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
Apr, 2038
(15 years from now) | |
| US11255842 | RADIUS HEALTH INC | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog |
Jan, 2040
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 28, 2022 |
| M | Sep 20, 2024 |
Drugs and Companies using ABALOPARATIDE ingredient
NCE-1 date: April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Method of treating postmenopausal women with osteoporosis at high risk for fracture.; Use for detecting neutralizing antibodies
Dosage: SOLUTION;SUBCUTANEOUS
27. List of Verzenio drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7855211 | ELI LILLY AND CO | Protein kinase inhibitors |
Dec, 2029
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 28, 2022 |
| New Patient Population (NPP) | Oct 12, 2024 |
| New Indication (I) | Oct 12, 2024 |
Drugs and Companies using ABEMACICLIB ingredient
NCE-1 date: September, 2021
Market Authorisation Date: 28 September, 2017
Treatment: In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; In combination with fulvestrant for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy; As monotherapy for the treatment of adult patients with hr-positive, her2-negative advanced or metastic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting; In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; In combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hr-positive, her2-negative, node-positive, early breast cancer at high risk of recurrence and a ki-67 score >=20%; In combination with fulvestrant for the treatment of adult patients with hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer with disease progression following endrocrine therapy; In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women, and men with hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer
Dosage: TABLET;ORAL
28. List of Vosevi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(5 years from now) | |
| US9585906 | GILEAD SCIENCES INC | NA |
Mar, 2028
(5 years from now) | |
| US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(5 years from now) | |
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(5 years from now) | |
| US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(5 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(6 years from now) | |
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(6 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(6 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(7 years from now) | |
| US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(7 years from now) | |
| US9868745 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(9 years from now) | |
| US8940718 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(9 years from now) | |
| US8575135 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(9 years from now) | |
| US8921341 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(9 years from now) | |
| US9296782 | GILEAD SCIENCES INC | Inhibitors of hepatitis C virus |
Jul, 2034
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8957046 | GILEAD SCIENCES INC | NA |
Mar, 2028
(5 years from now) | |
|
US8334270
(Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
|
US9085573
(Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
|
US8735372
(Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
|
US8580765
(Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
|
US8889159
(Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(6 years from now) | |
|
US7964580
(Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(6 years from now) | |
|
US8633309
(Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(6 years from now) | |
|
US9284342
(Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(8 years from now) | |
|
US8618076
(Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(8 years from now) | |
|
US8575135
(Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(10 years from now) | |
|
US8940718
(Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(10 years from now) | |
|
US8921341
(Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(10 years from now) | |
| US11116783 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(10 years from now) | |
|
US11116783
(Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) | |
| US10912814 | GILEAD SCIENCES INC | Combination formulation of three antiviral compounds |
Jun, 2037
(14 years from now) | |
| US11338007 | GILEAD SCIENCES INC | Combination formulation of three antiviral compounds |
Jun, 2037
(14 years from now) | |
|
US11338007
(Pediatric) | GILEAD SCIENCES INC | Combination formulation of three antiviral compounds |
Dec, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 18, 2022 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient
NCE-1 date: July, 2021
Market Authorisation Date: 18 July, 2017
Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor; Treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor
Dosage: TABLET;ORAL
29. List of Wegovy drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(3 years from now) | |
| US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9764003 | NOVO | Use of long-acting GLP-1 peptides |
Jun, 2033
(10 years from now) | |
| US10888605 | NOVO | GLP-1 compositions and uses thereof |
Aug, 2038
(15 years from now) | |
| US11318191 | NOVO | GLP-1 compositions and uses thereof |
Feb, 2041
(18 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 5, 2022 |
| New Product (NP) | Jun 4, 2024 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 04 June, 2021
Treatment: Method for weight management according to a dose escalation schedule; Method for weight management
Dosage: SOLUTION;SUBCUTANEOUS
30. List of Xadago drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8278485 | MDD US | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides |
Jun, 2027
(4 years from now) | |
| US8076515 | MDD US | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides |
Dec, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8283380 | MDD US | Methods for treatment of parkinson's disease |
Mar, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 21, 2022 |
Drugs and Companies using SAFINAMIDE MESYLATE ingredient
NCE-1 date: March, 2021
Market Authorisation Date: 21 March, 2017
Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes
Dosage: TABLET;ORAL
31. List of Xepi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6335447 | FERRER INTERNACIONAL | Quinolonecarboxylic acid derivatives or salts thereof |
Nov, 2023
(9 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9399014 | FERRER INTERNACIONAL | Pharmaceutical topical compositions |
Dec, 2029
(6 years from now) | |
| US9180200 | FERRER INTERNACIONAL | Pharmaceutical topical compositions |
Jan, 2032
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 11, 2022 |
Drugs and Companies using OZENOXACIN ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 11 December, 2017
Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes
Dosage: CREAM;TOPICAL
32. List of Xermelo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7553840 | TERSERA | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
Dec, 2027
(4 years from now) | |
| US8193204 | TERSERA | Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use |
Feb, 2031
(8 years from now) | |
| US7709493 | TERSERA | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
Feb, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7968559 | TERSERA | Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds |
Dec, 2027
(4 years from now) | |
| US8653094 | TERSERA | Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use |
Dec, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 28, 2022 |
| Orphan Drug Exclusivity (ODE) | Feb 28, 2024 |
Drugs and Companies using TELOTRISTAT ETIPRATE ingredient
NCE-1 date: February, 2021
Market Authorisation Date: 28 February, 2017
Treatment: The treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy
Dosage: TABLET;ORAL
33. List of Zejula drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8436185 | GLAXOSMITHKLINE | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide |
Apr, 2029
(6 years from now) | |
| US8071623 | GLAXOSMITHKLINE | Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors |
Mar, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071579 | GLAXOSMITHKLINE | DNA damage repair inhibitors for the treatment of cancer |
Aug, 2027
(4 years from now) | |
| US8143241 | GLAXOSMITHKLINE | DNA damage repair inhibitors for treatment of cancer |
Aug, 2027
(4 years from now) | |
| US8859562 | GLAXOSMITHKLINE | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(8 years from now) | |
| US11091459 | GLAXOSMITHKLINE | Niraparib compositions |
Mar, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 29, 2027 |
| New Chemical Entity Exclusivity (NCE) | Mar 27, 2022 |
| New Indication (I) | Apr 29, 2023 |
Drugs and Companies using NIRAPARIB TOSYLATE ingredient
NCE-1 date: March, 2021
Market Authorisation Date: 27 March, 2017
Treatment: A method of treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer associated with homologous recombination deficiency (hrd) positive status
Dosage: CAPSULE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic